Jpmorgan Chase & CO Acurx Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
30Shares Held
1.21MCall Options Held
14.3KPut Options Held
18.3K-
Vanguard Group Inc Valley Forge, PA492KShares$934,2050.0% of portfolio
-
Prospect Financial Services LLC Melville, NY278KShares$528,3900.48% of portfolio
-
Geode Capital Management, LLC Boston, MA130KShares$247,0280.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC53.7KShares$102,0960.0% of portfolio
-
Morgan Stanley New York, NY46.4KShares$88,1610.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $22M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...